
How Trump’s reshoring EO affects plans to build or expand a domestic drug manufacturing facility
Investments in new (“greenfield”) or expanded (“brownfield,” “retrofit”) domestic manufacturing capabilities require years of strategic planning and capital expenditure. Even with the announcement of near-term incentives and reduced regulatory complexities …